Jul 2026
Abstract B077: EMI-1725 Demonstrates Broad Antagonist Activity Against Drug-Resistant Androgen Receptor Mutations and Tumor Growth Suppression in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer
In vitro and in vivo findings support the advancement of EMI-1725 as a promising therapeutic candidate for mCRPC, which showed improved biodistribution across organs and displayed less accumulation in the brain compared to enzalutamide, where off-target binding leads to risk of seizure.
S. Kregel, R. J. Kostlan, John T. Phoenix et al.
· Clinical Cancer Research · 0 citations